Beam Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Beam Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Cambridge
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- BEAM
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001745999
Board of directors
-
Carole Ho · DirectorSince 2023
-
Chirfi Guindo · DirectorSince 2024
-
Christi Shaw · DirectorSince 2023
-
Graham K. Cooper · DirectorSince 2023
-
John M. Evans · Director · CEOSince 2023
- Since 2023
-
Kathleen E. Walsh · DirectorSince 2023
- Since 2023
-
Mark Fishman · DirectorSince 2023
Chief executives
John M. Evans
· CEO
Dates unknown
Director election results
Annual meeting of June 3, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
89.4%
-
90.5%
-
98.8%
Board connections
4 of this board's directors also sit on 14 other boards.
- via John Maraganore
- via Christi Shaw
- via Kristina Burow
- via Kristina Burow
- via John Maraganore
- via Kristina Burow
- via John Maraganore
- via Christi Shaw
- via Kristina Burow
- via John Maraganore
- via John Maraganore
- via Carole Ho
- via Kristina Burow
- via John Maraganore
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $19,804,225
- 33 sales by 7 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 24, 2026 | Ciaramella Giuseppe Officer (President) | Gift | −123,407 | — | — |
| Jul 27, 2026 | Simon Amy Officer (Chief Medical Officer) | Open-market sale | −16,667 | $25.74 | $429,037 |
| Jun 30, 2026 | Simon Amy Officer (Chief Medical Officer) | Open-market sale | −373 | $34.73 | $12,954 |
| Jun 30, 2026 | John M. Evans Director, Officer (CEO) | Option exercise | +25,000 | $1.03 | $25,750 |
| Jun 30, 2026 | John M. Evans Director, Officer (CEO) | Open-market sale | −23,100 | $34.26 | $791,482 |
| Jun 30, 2026 | John M. Evans Director, Officer (CEO) | Open-market sale | −1,900 | $34.84 | $66,203 |
| Jun 29, 2026 | John M. Evans Director, Officer (CEO) | Option exercise | +18,663 | $0.67 | $12,504 |
| Jun 29, 2026 | John M. Evans Director, Officer (CEO) | Option exercise | +6,337 | $1.03 | $6,527 |
| Jun 29, 2026 | John M. Evans Director, Officer (CEO) | Open-market sale | −13,421 | $35.13 | $471,528 |
| Jun 29, 2026 | John M. Evans Director, Officer (CEO) | Open-market sale | −11,579 | $35.91 | $415,824 |
| Jun 26, 2026 | FMR LLC 10% owner, See Remark 1 | Open-market sale | −251,488 | $35.26 | $8,867,467 |
| Jun 25, 2026 | FMR LLC 10% owner, See Remark 1 | Open-market sale | −33,372 | $35.12 | $1,172,025 |
| Jun 17, 2026 | Ciaramella Giuseppe Officer (President) | Option exercise | +6,505 | $0.67 | $4,358 |
| Jun 17, 2026 | Ciaramella Giuseppe Officer (President) | Option exercise | +29,000 | $1.03 | $29,870 |
| Apr 1, 2026 | John M. Evans Director, Officer (CEO) | Open-market sale | −30,078 | $24.58 | $739,317 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.